"selinexor+pegaspargase+dexamethasone"in ⅰ/ⅱ nktcl

Conditions: NKTCL; Selinexor

Summary: evaluate the efficacy and safety of "selinexor+pegaspargase+dexamethasone" in early stage nk/ t-cell lymphoma

patients with early nk/t cell lymphoma were treated with an oral regimen of \&#34;selinisol + pemaspartase + dexamethasone\&#34;

Eligibility criteria:
inclusion criteria: 1. age 18-70 years old, ecog score 0-2; (including those aged 18 and 70); 2. pre-survival time \&gt; 6 months; 3. the pathological tissue was confirmed as nk/t cell lymphoma (the pathological report of the first three months of enrollment could be accepted) (note: if there is any doubt about the pathological diagnosis, domestic third-party consultation could be organized); 4. clinical stage ⅰ to ⅱ (ca stage) with at least one measurable lesion; 5. acceptable hematological indicators, no contraindications to chemotherapy; neutrophil absolute value ≥1.0×10\^9 /l, platelet ≥75×10\^9 /l, hemoglobin ≥80g/l (except patients with lymphoma bone marrow infiltration); 6. liver function: direct bilirubin ≤1.5× upper limit reference value; glutamic pyruvic transaminase or glutamic oxalacetic transaminase ≤2.5× upper limit reference value; alkaline phosphatase ≤3×uln in non-bone invaded patients; 7. renal function: serum creatinine ≤1.5×uln; 8. female and male patients of reproductive age and their spouses are willing to use adequate contraception throughout the study period, and female patients of reproductive age must have a negative serum pregnancy test within 7 days before the first dose; 9. the newly treated patient had not received other tumor-related treatment in the past; 10. subjects voluntarily participate in the clinical trial, sign informed consent, and cooperate with follow-up; exclusion criteria: 1. refuse to collect blood samples; 2. previous allergy to any of the drugs in the program; 3. pregnant and lactating women; 4. major diseases that the investigator believes can cause interference with the test; 5. combined with other tumors; 6. there are contraindications related to therapeutic drugs in the program; 7. persons with serious mental illness; 8. participating in other clinical trials; 9. previous anti-tumor therapy (such as radiotherapy, chemotherapy, hormone therapy, biotherapy, immunotherapy); 10. other serious medical conditions that may limit participants\&#39; participation in the trial, such as uncontrolled diabetes; severe cardiac insufficiency (nyha grade ii or above); acute coronary syndrome within the last 6 months; coronary revascularization such as stenting, coronary artery bypass surgery, and other heart and large vessel related procedures within the last 6 months; severe arrhythmias include frequent ventricular early, ventricular tachycardia, rapid atrial fibrillation/flutter, and severe bradycardia. uncontrolled hypertension: systolic blood pressure \&gt;150mmhg, diastolic blood pressure \&gt;100mmhg. gastric ulcers (stomach ulcers that researchers have determined are at risk of perforation); active autoimmune diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, sjogren\&#39;s syndrome, autoimmune thrombocytopenia, etc.); severe respiratory disease (such as obstructive pulmonary disease and a history of bronchospasm); 11. hemophagic cell syndrome; 12. researchers do not consider it suitable for inclusion; 13. hepatitis b core antibody (hbcab) positive and peripheral blood hepatitis b virus (hbv) dna titer detection is not within the normal reference value range; hepatitis c virus (hcv) antibody positive and peripheral blood hepatitis c virus (hcv) rna positive; human immunodeficiency virus (hiv) antibody positive; syphilis test positive.

Keywords: nktcl selinexor